Endocrine Therapy for Early -and Late- Stages Breast Cancer: Therapeutic Updates
By: Joyce O’Shaughnessy, MD
Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies (Part 2)
By: Joyce O’Shaughnessy, MD
Antibody Drug Conjugates Expanding a Targeted Assault on all Breast Cancer Subtypes
By: Komel Jhaveri, MD
Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)
By: Lajos Puzstai, MD, DPhil, FASCO
Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)
By: Lajos Puzstai, MD, DPhil, FASCO
Post-Neoadjuvant Therapy after Residual Disease: How to Approach This Problem?
By: Lauren Carcas, MD
Post-Neoadjuvant Therapy after Residual Disease: How to Approach This Problem?
By: Lauren Carcas, MD
Understanding Mechanisms of ADC Resistance: Lessons Learned and New Directions
By: Leif Ellisen, MD, PhD
Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer
By: Mariana Chavez MacGregor, MD, MSc, FASCO
Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer
By: Mariana Chavez-McGregor, MD, MSc, FASCO
Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer
By: Mariana Chavez-McGregor, MD, MSc, FASCO
